Navigation Links
Agent selectively targets malignant B cells in chronic leukemia, study shows
Date:5/3/2011

COLUMBUS, Ohio A new experimental drug selectively kills the cancerous cells that cause chronic lymphocytic leukemia, according to a new study by researchers at the Ohio State University Comprehensive Cancer Center Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC James).

The study shows that the experimental agent PCI-32765 selectively kills the malignant B lymphocytes that cause chronic lymphocytic leukemia (CLL).

The researchers say the findings, published online in the journal Blood, are important because current CLL therapies kill T lymphocytes along with the cancerous B lymphocytes.

T lymphocytes and B lymphocytes make up the adaptive immune system. When CLL treatment destroys them both, patients become highly susceptible to life-threatening infections.

"A drug that kills malignant B lymphocytes and spares T lymphocytes could dramatically improve outcomes for CLL patients," says study leader Dr. John C. Byrd, director, division of hematology and professor of medicine, of medicinal chemistry and of veterinary biosciences at the OSUCCC James.

"Our collective results indicate that PCI-32765 is an outstanding candidate for further development as a therapeutic for CLL," says study co-director Dr. Amy J. Johnson, assistant professor of hematology and medicinal chemistry, and a CLL researcher with the OSUCCC-James.

The research by Byrd, Johnson and a group of colleagues used CLL cells from ten patients. It had several key findings related to PCI-32765:

  • The agent specifically targets an important signaling molecule called Bruton's tyrosine kinase, which is overexpressed in CLL cells and absent in T cells.
  • The agent inhibits the proliferation of CLL cells in laboratory culture and promotes their death by self-destruction (apoptosis).
  • It blocks survival signals from cells in the surrounding microenvironment, including soluble factors such as IL-6, IL-4, and TNF-α, and stromal-cell contact.


'/>"/>

Contact: Darrell E. Ward
Darrell.Ward@osumc.edu
614-293-3737
Ohio State University Medical Center
Source:Eurekalert

Related medicine news :

1. Professional Insurance Agents to Hold 2010 Federal Legislative Summit March 17-18
2. Long Term Care Insurance Leader Seeks 320 New Agents in 2010, Following Strong 2009 Growth
3. Professional Insurance Agents Name Rep. Charlie Melancon 2010 Legislator of the Year
4. Overcoming tumor resistance to anti-cancer agent TRAIL
5. Scott & White Healthcare researchers studying investigational agent that targets breast cancer
6. Targeted agent blocked growth of deadly brain cancer in preclinical studies
7. New agent chokes off energy supply, kills cancer cells
8. Health Insurance Agents Work with Zane Benefits to Offer New Solutions amid Health Care Reform
9. Mayo-led research team develop agents that keep insulin working longer
10. Shark cartilage shows no benefit as a therapeutic agent for lung cancer
11. Compound enhances cancer-killing properties of agent in trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... ... The American Board of Family Medicine's (ABFM) Board of Directors has selected Warren ... James C. Puffer upon his retirement. Dr. Newton will serve in the position of ... end of 2018. Upon assuming the role of President and CEO on January 1, ...
(Date:10/13/2017)... (PRWEB) , ... October 13, ... ... School of Pharmacy (SOP) alumni Hannah Randall, PharmD ‘17, and Jennifer Huggins, ... professionals on guideline updates for the primary prevention of cardiovascular diseases during ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Many families ... However, many long-term care insurance companies have a waiver for care if the client ... elimination period, when the family pays for care, is often waived, so the benefits ...
(Date:10/13/2017)... ... October 13, 2017 , ... Global Healthcare Management’s 4th Annual Kids Fun ... NJ. This free event, sponsored by Global Healthcare Management’s CEO, Jon Letko, is ... is geared towards children of all ages; it is a non-competitive, non-timed event, which ...
(Date:10/13/2017)... ... 13, 2017 , ... Coveros, a leader in agile coaching ... contract by the Center for Medicare and Medicaid Services (CMS). The Enterprise Agile ... of Agile methodologies in a consistent and high value manner across CMS programs. ...
Breaking Medicine News(10 mins):
(Date:10/10/2017)... --  West Pharmaceutical Services, Inc. (NYSE: WST), a ... today shared the results of a study highlighting the ... administration of polio vaccines. The study results were presented ... by Dr. Ondrej Mach , Clinical Trials and ... and recently published in the journal Vaccine. i ...
(Date:10/4/2017)... , Oct. 4, 2017  According to the Centers for Disease ... end of October . PhysicianOne Urgent Care is helping communities across ... Westchester, NY , by offering no-cost* flu shots through the end ... mandated by certain health insurance regulations. ... The best time to get a flu shot is by the end ...
(Date:10/2/2017)... Oct. 2, 2017  AllianceRx Walgreens Prime, the combined ... Walgreens and pharmacy benefit manager Prime Therapeutics LLC (Prime), ... which included the unveiling of new signage at its ... well as at a few other company-owned facilities across ... to patients, some of whom will begin to see ...
Breaking Medicine Technology: